The Motley Fool

Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.
The Motley Fool

Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

Recursion Pharmaceuticals is a TechBio company trying to apply artificial intelligence (AI) to the new drug-discovery process. The first placebo-controlled trial results from Recursion Pharmaceuticals ...
JSTOR Daily

The Recursive Process In and Of Critical Literacy: Action Research in an Urban Elementary School

Canadian Journal of Education / Revue canadienne de l'éducation, Vol. 35, No. 2 (2012), pp. 41-57 (17 pages) Abstract This paper provides an overview of the recursive process of initiating an action ...
Nasdaq

Recursion Pharmaceuticals’ (RXRX) Bold Acquisition Places it as an Industry Leader

Recursion Pharmaceuticals (RXRX), a trailblazer in AI-powered drug discovery, recently acquired its competitor, Exscientia, in a strategic move that solidifies its leading position in the industry.
JSTOR Daily

A Necessary and Sufficient Condition for the Tail-Triviality of a Recursive Tree Process

This is a preview. Log in through your library . Abstract Given a recursive distributional equation (RDE) and a solution μ of it, we consider the tree indexed invariant process called the recursive ...
Business Insider

Recursion Secures $1.6M NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, a Key Age-Related Disease Process

SALT LAKE CITY, Nov. 8, 2018 /PRNewswire/ -- Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop ...